The Expert Angle
Medlior is a well-known and trusted industry leader.
Our team is dedicated to delivering high-quality research that provides a solid basis for informed decision-making.
Medlior’s Expert Angle offers the inside track on new studies, industry hot topics, and what you need to know in the fast-paced world of clinical research, all from the point of view of the Medlior team of experts. From the latest topics and trends to the foundations of health and medical research, Medlior explores topics relevant to clients and the world.
Epidemiology, Treatment Landscape, and Healthcare Resource Utilization for Patients with Migraine in Canada: A Literature Review
Synthetic Data and Real-World Evidence Studies
What is Synthetic Data?
Synthetic data is the generation of realistic datasets that capture important relationships and information from real-world data. These datasets are created through random sampling models, such as Bayesian or neural networks, with the help of domain experts to validate ...
COVID-19 and Opioid Overdose Deaths: Insights from Alberta’s Substance Use Surveillance Data
People who use drugs, particularly opioids, are a group that has been disproportionately impacted by the COVID-19 pandemic. Safe consumption sites and homeless shelters are supports often relied upon by people who use drugs. During the pandemic, these supports have been, in some cases, ...
Medlior Publications
Explore a list of all of Medlior's recent publications including recent Medlior evidence generation publications and recent Medlior RWE publications.
Recent Medlior RWE publications
Scory T, Chen G, Farris M, Shih YH, Pinto L, Cowling T. Lipid-lowering therapy patterns and low-density ...
The effects of COVID-19 on Cancer screening
Across the globe, the COVID-19 pandemic has negatively impacted healthcare delivery including:
delays in elective or non-urgent surgeries and procedures,
disruptions to cancer screening, and
cessation of routine laboratory tests.
In Canada, the Canadian Institute for Health ...
The Canadian Survey on Disability: An Underutilized Source for Measuring Burden of Illness
The Canadian Survey on Disability (CSD) is a repeated cross-sectional survey of Canadians 15 years of age and older living with disability.1 Conducted by Statistics Canada, CSD participants are recruited from individuals who reported having a long-term health related condition or difficulty on ...
Report on virus-neutralizing monoclonal antibodies for the treatment of SARS-CoV-2
Medlior was pleased to work with the Canadian Agency for Drugs and Technologies in Health (CADTH) to prepare a report on virus-neutralizing monoclonal antibodies for the treatment of SARS-CoV-2 infection, as part of CADTH’s Coronavirus Disease (COVID-19) evidence bundle.
The Medlior team ...
Looking Forward for 2021
In January of 2020, we started the year with a passion for innovation and collaboration to produce impactful health outcomes research projects. We certainly could not have predicted the year that would follow, and while it was unprecedented, it also emphasized the vital role of health research ...
Looking back on 2020 – a year no one predicted
There’s not much that can be said about 2020 that hasn’t already been said. Unpredictable, unprecedented, unparalleled, 2020 will be remembered for a lot of things.
But as we look towards 2021, we’re seeing hope like we haven’t seen in many months. With vaccines getting approved from ...
Calgary business owner, Tara Cowling, named Top 100 Female Entrepreneurs in Canada
The top 100 Canadian businesses are presented by Scotiabank Women Initiative, the National Post, and Visa Canada
Calgary, AB (December 1, 2020) - Calgary business owner and founder of Medlior Health Research Outcomes Ltd, Tara Cowling, has been named as one of the Top 100 female entrepreneurs ...
Indirect analysis of first-line therapy for advanced non-small cell lung cancer with activating mutations in the Japanese population
Medlior presents the recent publication, “Indirect analysis of first-line therapy for advanced non-small cell lung cancer with activating mutations in the Japanese population,” on first-line treatments of epidermal growth factor receptor mutation positive (EGFR+) non small cell lung cancer ...
Network meta-analysis of first-line therapy for advanced Epidermal Growth Factor Receptor mutation positive non-small cell lung cancer
Updated overall survival on the first-line treatments for advanced epidermal growth factor receptor mutation positive non-small cell lung cancer
Lung cancer is the leading cause of death in Canada, with approximately 29,300 Canadians developing lung cancer in 2019.1 There are two forms of ...
